Genetic Polymorphisms and Cisplatin- Related Nephrotoxicity
<p>Cis- diamminedichloroplatinum (cisplatin) is one of the most commonly used present day hemotherapeutic agents. It is used to treat a wide range of cancers including head and neck, lung, gastrointestinal tract, ovarian and genitourinary cancers. However, dose- limiting toxicity is often asso...
Saved in:
Main Authors: | Arundhati Bag (Author), Lalit Mohan Jeena (Author), Niladri Bag (Author) |
---|---|
Format: | Book |
Published: |
Global Journal of Cancer Therapy - Peertechz Publications,
2015-01-07.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review
by: Zulfan Zazuli, et al.
Published: (2018) -
Cisplatin therapy and the problem of gender-related nephrotoxicity
by: Nasri Hamid
Published: (2013) -
Prevention of cisplatin nephrotoxicity
by: Hayati Fatemeh, et al.
Published: (2016) -
Glutamine protects against cisplatin-induced nephrotoxicity by decreasing cisplatin accumulation
by: Hyun-Jung Kim, et al.
Published: (2015) -
Renoprotective effects of antioxidants against cisplatin nephrotoxicity
by: Hajian Shabnam, et al.
Published: (2014)